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ORIGINAL ARTICLE
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Preventive Medicine, and 6Department of Microbiology, Immunology, and Biochemistry, University of Tennessee Health Science Center,
Memphis, Tennessee; and 5Children’s Foundation Research Institute, Le Bonheur Children’s Hospital, Memphis, Tennessee
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Abstract
Rationale: Studies of the immune responses at the site of respiratory
syncytial virus (RSV) infection are sparse despite nearly five decades
of research into understanding RSV disease.
Objectives: To investigate the role of mucosal innate immune
responses to RSV and respiratory viral load in infants hospitalized
with the natural disease.
Methods: Cytokines, viral load, and type 2 innate lymphoid cell
(ILC2) levels in nasal aspirates, collected within 24 hours of
enrollment, from infants hospitalized with RSV infection were
quantified.
Measurements and Main Results: RSV severity in infants was
categorized based on admission to the generalward (moderate) or the
pediatric ICU (severe). Evaluable subjects included 30 patients with
severe and 63 patients with moderate disease (median age, 74 d;
range, 9–297 d). ILC2s were found in the nasal aspirates of patients
with severe disease (0.051% of total respiratory CD451 cells) to a
significantly greater extent than in patients with moderate disease
(0.018%, P= 0.004). Levels of IL-4, IL-13, IL-33, and IL-1b were
significantly higher in nasal aspirates of patients with severe disease
compared with those of patients with moderate disease. Factors
associated with disease severity were gestational age (odds ratio, 0.49;
95% confidence interval, 0.29–0.82; P= 0.007) and IL-4 (odds ratio,
9.67; 95% confidence interval, 2.45–38.15; P= 0.001).
Conclusions:This study shows, for thefirst time, that elevated levels
of ILC2s is associatedwith infant RSV severity. Thefindings highlight
the dominance of type-2 responses to RSV infection in infants and
suggest an important role of ILC2 in shaping the immune response
early during RSV infection.
Keywords: type 2 innate lymphoid cell; infant; respiratory
syncytial virus; severity; immune response
Respiratory syncytial virus (RSV) is the
leading cause of acute lower respiratory tract
infection and severe bronchiolitis in infants
globally (1). Age at initial RSV infection is a
major predictor of disease severity (2–4).
However, the reason that infants are more
susceptible to severe RSV infection
and severe disease remains unclear.
Manifestations of severe RSV infection
include respiratory insufficiency and severe
apnea that requires admission to the
pediatric ICU (PICU) and mechanical
ventilator support. Although a licensed
immunoprophylactic for RSV
(palivizumab) exists and effectively reduces
RSV hospitalization rates (5), there is no
vaccine or specific antiviral treatments
approved for use in infants. Currently, the
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mainstay for the treatment of severe RSV
disease is supportive care.
In humans, both viral load (3, 4) and T-
helper cell type 2 (Th2)-biased responses,
characterized by exacerbated IL-4 and IL-
13 secretion and low IFN-g, have been
associated with RSV pathogenesis (6).
Recent studies have suggested the critical
role of type 2 innate lymphoid cells (ILC2s)
in shaping and promoting Th2 responses in
respiratory and pulmonary compartments
in humans (7–9). ILC2s, together with
ILC1s and ILC3s, are characterized as rare
innate immune cells with lymphoid
morphology, but phenotypically distinct
from T, B, and myeloid cells (10). Despite
their scarcity, ILC2s are the primary ILC
population in the lung and rapidly secrete
large amounts of type 2 cytokines upon
airway inflammation (7). Using a novel
neonatal mouse model, we previously
demonstrated that the rapid increase in
pulmonary ILC2s, which is driven by
robust induction of IL-33, coincided with
Th2-biased responses after RSV neonatal
infection (11). These studies implied the
key role of ILC2 as the early responders to
RSV infection and demonstrated their
central role in orchestrating the subsequent
adaptive immune response. Although IL-33,
a known inducer of ILC2s (12), has been
detected at higher levels in infants with RSV
bronchiolitis compared with healthy control
infants (11, 13), no data exist on respiratory
ILC2 in RSV-infected infants. In the current
study, we describe the early infant immune
response to RSV infection and viral load at
the site of initial infection. Our studies were
performed on nasal aspirates isolated from
infants infected with RSV and hospitalized at
Le Bonheur Children’s Hospital (Memphis,
TN). We hypothesized that elevated levels
of ILC2 and their associated cytokines (IL-13
and IL-4) and inducing cytokine (IL-33) are
positively correlated with RSV severity in
infants early during infection.
Methods
For a detailed description, see the online
supplement.
Study Participants
The study was approved by the Institutional
Review Board of the University of Tennessee
Health Sciences Center. The selection criteria
are described in Table E1 in the online
supplement. RSV infection was confirmed in
the research laboratory using RSV-PCR, as
previously described (14). We compared
moderately (admitted to the general ward)
and severely (admitted to PICU) RSV-
infected infants admitted to Le Bonheur
Children’s Hospital from 2013 to 2016.
Nasal Aspirate Collection and
Quantification of Viral Load and
Cytokine Levels
Nasal aspirates were collected within
24 hours of enrollment. Supernatants from
nasal aspirates were centrifuged at 1,0003 g
for 3 minutes, and 250-ml aliquots were
stored at 2808C until use. The cell pellet
was washed twice by gently mixing with 5 ml
of RPMI-1640 and then filtered through a
40-mm cell strainer before being
centrifuged at 3,0003 g for 3 minutes.
Pelleted cells were suspended in
Recovery Cell Culture Freezing Medium
(ThermoFisher) at 33 106 cell/ml, and
1-ml aliquots were stored at 21508C until
use. The viral load and cytokine levels in
the nasal aspirate were quantified with
qRT-PCR and multiplex assay (Meso Scale
Discovery), respectively.
Flow Cytometry Analysis
Frozen cells were thawed using CTL
antiaggregate wash solution (ImmunoSpot)
once in RPMI-1640 (CTL buffer). Briefly,
the vial of cells was quickly thawed in a 378C
bead bath until the ice chunk was released
from the wall of the tube. The cells were
then added to 9 ml of 378C CTL buffer. The
thawed cells were subsequently washed
twice with 10 ml of warm CTL buffer with
centrifugation at 5003 g for 5 min at room
temperature. The resulting cells were
suspended in 250 ml of warm CTL buffer.
Approximately 105–106 nasal aspirate cells
were sequentially stained with human Fc
blocking (CD16/CD32) and a panel of
monoclonal antibodies at 48C for 30
minutes. The stained cells were then fixed
before flow cytometric analysis with a BD
FACSCanto II flow cytometer and
subsequently FlowJo v.10. ILC2s were identified
as CD451Lin2CD1271CD1611CRTH21c-
kit2 with gating based on fluorescence
minus one controls. The antibody panel
and gating strategy are described in Table
E4 and Figure E1, respectively.
Statistical Analysis
The data are described using descriptive
statistics. Comparisons were performed
using a two-tailed Mann-Whitney U test for
continuous variables and chi-square or
Fisher’s exact test for qualitative and
categorical variables. We examined the
relationship of all variables with the
outcome of disease severity and computed
unadjusted odds ratios (ORs) with 95%
confidence interval (CI) using bivariate and
multivariable logistic regression. Analyses
were performed using SAS v9.3 (SAS
Institute Inc.).
Results
Characteristics of Infants Enrolled
with RSV Infection
Subjects included 30 severely
(PICU) and 63 moderately (non-
PICU) infected infants with RSV
hospitalized from 2013 to 2016. Subjects
had a median age of 70.5 (patients with
severe disease) and 78 (patients with
moderate disease) days, respectively
(Table 1). Most infants with severe RSV
were mechanically ventilated (86.7%) and
At a Glance Commentary
Scientific Knowledge on the
Subject: The severity of respiratory
syncytial virus (RSV) infection in
human infants has been related to
type 2–biased immune responses.
Although there is a great body of
animal studies providing mechanistic
insights into the role of peripheral
innate lymphoid type 2 cells (ILC2s)
in mediating type 2 responses in
different lung diseases, direct evidence
of the involvement of respiratory ILC2
in infant RSV severity is lacking.
What This Study Adds to the Field:
This study, for the first time, reveals the
association of elevated levels of
respiratory ILC2 and their associated
cytokines with RSV severity in infants
during the early phase of infection at
the site of initial infection using nasal
aspirates. Thus, these findings provide
not only a new insight about the local
innate immune responses, but also a
translation from animal models to
human patients, and they suggest the
important role of ILC2s in shaping the
immune response in the early phase of
RSV infection.
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hospitalized for a longer period compared
with infants with moderate RSV (Table 1).
This supports the classification of disease
severity based on PICU status.
The median gestational ages (GAs)
were 36 and 38.3 weeks (Table 1) for severe
and moderate groups, respectively. In
addition, 56.7% of infants with severe RSV
had GA ,37 weeks (preterm infants); this
is higher than 30.2% of infants with
moderate RSV. Admission to the neonatal
ICU (NICU) at birth also differed with
severity with 53.3% of infants with severe
RSV and only 28.6% of infants with
moderate RSV having been admitted to the
NICU. Infants in the two study groups were
not equally distributed according to race.
White race constitutes 53.3% of total severe
cases compared with 36.5% of total
moderate cases (Table 1). There is also
no significant difference between the
median days of duration of symptoms
before collection of samples of patients
with severe disease (3.5 d) and that of
patients with moderate disease (4 d)
(Table 1).
Global Respiratory Cytokine Profiles
Are Associated with RSV Disease
Severity at the Early Phase of the
Disease
To explore the association between immune
responses and disease severity, we
conducted principal component (PC)
analysis (PCA) on 13 continuous immune-
related variables (11 cytokines, ILC2s, and
viral load). Then, PCA maps were colored
by sex, race, and RSV subtype, past NICU
stay, mechanical ventilation, and PICU
admission. Figure 1 illustrates our PCA
analysis with immune-related variables,
with the first and second PCs (PC1 and
PC2) accounting for 26.6% and 19.7%,
respectively, of all the variance of immune
mediators. Thus, in contrast to other
demographic variables (sex, race, RSV type,
and NICU status), PICU and mechanical
ventilation status form discrete clusters
with limited overlap (Figure 1A).
Interestingly, IL-1b, IL-13, IL-4, IL-33, and
ILC2s of infants with severe RSV grouped
together and situated opposite to IFN-g,
TNF (tumor necrosis factor), IL-12, IL-17A,
and IL-22 of infants with moderate RSV
group (Figure 1B) implying that analyzed
immune mediators were associated with
disease severity and independent of sex,
race and RSV type.








Age, median (range), d 70.5 (11–297) 78 (9–288)
Age <3 mo old, n (%) 20 (66.7) 37 (58.7)
Age .3 mo old, n (%) 10 (33.3) 26 (41.3)
Gestational age, median (range), wk 36 (32–40) 38.3 (30–41)
Preterm, n (%)
No 13 (43.3) 44 (69.8)
Yes 17 (56.7) 19 (30.2)
Birthweight, median (range), lb* 5.5 (3.9–8.7) 6.7 (1.3–9.5)
Enrollment weight, median (range), lb 10.7 (5.0–19.4) 12 (5.9–24.7)
Sex, n (%)
Male 17 (56.7) 41 (65.1)
Female 13 (43.3) 22 (34.9)
Race, n (%)
White 16 (53.3) 23 (36.5)
African American 11 (36.7) 39 (61.9)
Others (Asian1Hispanic) 3 (10) 1 (1.6)
History of being in NICU, n (%)
No 14 (46.7) 45 (71.4)
Yes 16 (53.3) 18 (28.6)
Time in NICU, median (range), d 14 (7–30) 14 (8 - 30)
Breastfeeding, n (%)*
No 12 (41.4) 30 (47.6)
Yes 17 (58.6) 33 (52.4)
Sick contact, n (%)
No 11 (36.7) 19 (30.2)
Yes 19 (63.3) 44 (69.8)
History of wheezing, n (%)
No 21 (70) 51 (81)
Yes 9 (30) 12 (19)
Exposure to tobacco, n (%)
No 23 (76.7) 55 (87.3)
Yes 7 (23.3) 8 (12.7)
Day care, n (%)
No 25 (83.3) 51 (80.9)
Yes 5 (16.7) 12 (19.1)
Parental smoking, n (%)
No 23 (76.7) 46 (73)
Yes 7 (23.3) 17 (27)
History of family asthma, n (%)
No 17 (56.7) 24 (38.1)
Yes 13 (43.3) 39 (61.9)
Fever, n (%)
No 16 (53.3) 30 (47.6)
Yes 14 (46.7) 33 (52.4)
Duration of symptoms before collecting of
nasal aspirates, median (range), d
3.5 (1–7) 4 (2–12)
Oxygen supplementation, n (%)*
No 0 (0) 15 (24.2)
Yes 30 (100) 47 (75.8)
LOS, median (range), d 15 (4–103) 4 (1–25)
DOS, median (range), d 3.5 (1–7) 4 (2–12)
Mechanical ventilation, n (%)
No 4 (13.3) 63 (100)
Yes 26 (86.7) 0 (0)
RSV subtype
A 22 (73.3) 37 (58.7)
B 8 (26.7) 26 (41.3)
Definition of abbreviations: DOS=duration of oxygen supplement; LOS= length of stay;
PICU=pediatric ICU; NICU= neonatal ICU; RSV= respiratory syncytial virus.
Preterm indicates gestational age ,37 weeks; breastfeeding was self-reported by parents; sick
contact indicates if the patient recently had contact with sick individuals before this illness; history of
wheezing indicates if the patient ever wheezed before this illness; exposure to tobacco smoke
indicates if the patient has ever been exposed to tobacco smoke before this illness; day care indicates
if there are more than than five children at the day care; parental smoking was self-reported by
parents; history of family asthma indicates if there is anyone in the family that has asthma, including
mother, father, brothers, or sisters; and fever indicates, with this illness, if the patient had run a fever
before being admitted to the hospital.
*Missing one data point.
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Type 2 Immunity Is Associated with
Severity of RSV Disease in Infants
Indeed, the moderate group displayed more
elevated levels of IFN-g, IL-12p40, and IL-
17A compared with infants with severe
RSV (Figures 2A, 2H, and 2I). Conversely,
the level of respiratory type 2 cytokines (IL-
4 and IL-13) and IL-33 were significantly
higher in the severe group related to the
moderate group (Figures 2D–2F). It
suggests that, although infants with severe
RSV displayed a predominance of type 2
cytokines in response to RSV infection, type
1 and type 3 cytokines were preferentially
expressed in patients with moderate RSV.
The Frequency of ILC2, but Not Viral
Load, Is Significantly Associated with
RSV Severity
Intriguingly, the frequency of ILC2, a central
mediator of type 2 immunity, was
significantly greater in infants with severe
versus moderate RSV (Figures 3A and 3B).
Similar observations were made by
comparing the absolute numbers of ILC2
and total cell counts in nasal aspirates
between infants with moderate RSV and
those with severe RSV (Figure E1C).
Examining viral load from nasal aspirates
obtained within 24 hours of enrollment, we
found that viral load was not significantly
different between moderate and infants
with severe RSV (Figure 3C). Similarly,
there was no noticeable association between
viral load with age at enrollment, sex, race,
prematurity, or NICU status (Figure E2).
Levels of Type 1 and Type 2 Immune
Mediators Are Age Dependent
We next examined the relationship between
immune/viral mediators and demographic
characteristics of RSV-infected infants.
Younger-GA infants tended to have higher
levels of IL-4, IL-13, and ILC2 and clustered
together. This clustering was distinct from
the IFN-g, IL-12, and IL-17A cluster
(Figure 3D). However, there was no
statistically significant correlation between
GA and any cytokines, ILC2s, or viral load
(Figure 3E). In addition, patients with
higher IL-4 levels tended to have high levels
of IL-13, IL33, and IL-1b, and relatively
high ILC2 frequency and lower IFN-g
(Figures 3D and 3E). Of note, most type 2
cytokines exhibited a positive correlation
with other type 2 cytokines, as well as with
ILC2. The levels of IL-4 were negatively
correlated with that of IFN-g (Figure 3E).
Similarly, there is a highly positive
correlation among type 3 cytokines
(Figure 3E).
Intriguingly, levels of IL-4 and ILC2 in
nasal aspirates were remarkably lower in
RSV-infected infants over 3 months
compared with infants 3 months of age or
younger (Figures 3F and 3G). Conversely,
IFN-g levels were significantly higher in
RSV-infected infants over 3 months
compared with infants 3 months of age or
younger (Figure 3H). The 3-month cutoff
of age at enrollment was selected based on
the age distribution of our cohort (Figure
E3A). Similar to IL-4, the levels of IL-13
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Figure 1. Immune mediators define disease severity. Principal component (PC) analysis (PCA) of 13 continuous immune-related variables (including viral
load) from 93 subjects was used to identify the first PCs (PC1 and PC2), which together explain 46.3% of the variation in the data. (A) PCA maps (or scores
plots), which show the scores on each PC for each infant. Then, PCA maps were colored by sex, race, respiratory syncytial virus (RSV) type, neonatal ICU
(NICU) status, and mechanical ventilation and pediatric ICU (PICU) status (from left to right). Individual points represent individual infants. Infants that are
close together have similar profiles of immune mediators (including viral load). The ellipses (with 95% confidence interval) depict a separation between two
different populations. (B) PCA biplot (or loading plot) shows the immune mediators, which load on the respective PCs. The vectors represent individual
immune mediators. Type II cytokines covary, as evidenced by clustering within the same quadrants of the PCA biplot. The color of vectors represents the
loading of the contribution of the individual immune mediators. WBN=well-baby nursery.
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the younger RSV-infected group (Figures
E3B and E3C). Of note, the majority of
patients with undetectable IL-13 and IL-33
had the moderate disease and was
significantly older at enrollment (Figure
E3D). There was no significant association
between GA and IL-13/IL-33 level
(Figure E3D).
Elevated Levels of Respiratory IL-4
and Young GA Are Significant Risk
Factors for Severe RSV Disease
The relationship of individual variables with
the outcome of disease severity was
examined using bivariate logistic regression
(Figure 4). The risk of RSV severity was
increased in infants with younger GA (OR,
0.59; 95% CI, 0.38–0.93; P= 0.021;
Figure 4A and Table E5A). Furthermore,
infants admitted to NICU were at higher
risk for severe disease relative to well-born
babies (OR, 2.86; 95% CI, 1.16–7.04;
P= 0.023; Figure 4A and Table E5A).
Intriguingly, infants with higher levels of
respiratory IL-4 and IL-1b were at
increased risk of severe RSV disease (IL-4:
OR, 6.71; 95% CI, 2.06–21.89; P= 0.002; IL-
1b: OR, 2.23; 95% CI, 1.24–4.00; P= 0.007;
Figure 4B and Table E5A). The risk of
severe disease also significantly increased in
infants with detectable levels of IL-13 or IL-
33 (Figure 4B and Table E5A) and infants
with higher frequencies of ILC2, but in a
marginally significant manner (OR, 1.55;
95% CI, 0.986–2.44; P= 0.057) (Figure 4B
and Table E5A). However, only IL-4 and
GA were retained as potential risk factors in
the final multivariable logistic regression
model (IL-4: OR, 9.67; 95% CI, 2.45–38.16;
P= 0.001; GA: OR, 0.49; 95% CI, 0.29–0.82;
P= 0.007; Table E5B). Figure 4C illustrates
the combined influence of IL-4 and
GA on infant RSV severity in the final
multivariable logistic regression. The effect
of IL-4 was greater at younger GA and
progressively reduced to negligible levels, at
,0.39 pg/ml. Thus, for a 37-week GA
patient, the probability of developing severe
RSV increases 24.4% (from 3.9% to 28.3%)
as the level of IL-4 in nasal aspirate
increases from 0.39 pg/ml to 0.52 pg/ml.
However, for a patient with younger GA
(30 wk), the probability of severe RSV
increases 50.6% (from 19.4% to 70%) as the
level of IL-4 increases from 0.39 pg/ml to
0.52 pg/ml. Therefore, younger GA and
higher IL-4 levels result in the highest


































































































Figure 2. Infants with severe respiratory syncytial virus disease express higher levels of type 2 cytokines. Cytokine expression in nasal aspirates, collected
within 24 hours of enrollment, was compared between patients with severe (n=30) and moderate disease (n=63) and are represented as box-and-
whisker plots. Whiskers represent maximum and minimum values; boxes represent 25th–75th percentiles. The median is represented by the middle line.
Significance was determined using the Mann-Whitney U test. *P< 0.05, **P<0.01, and ****P<0.0001. LLOQ= lower limit of quantification; LOD= limit of
detection; ns= nonsignificant.
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probability for severe RSV. The final
multivariable results are exploratory, and
all analyses should be examined further
and validated in similar cohorts.
Discussion
Our study confirms that preterm birth is a
major risk factor for severe RSV disease,
including the requirement of mechanical
ventilation and longer length of stay (LOS)
(15–18). The younger the GA, the greater
the risk of severe disease (Figures 4A and
4C and Table E5). After discharge from the
NICU, preterm infants are more often
rehospitalized with lower respiratory tract
infections, presumably due to reduced
immunoglobulin concentrations and
immature immune systems. GA is
positively correlated with the level of
maternal immunoglobulins (18–20), and
the expression of CD14 and MD-2 on
leukocytes (21), which plays an important
role in RSV fusion protein–mediated
Toll-like receptor 4 activation (22).
Interestingly, the impairment of CD14 and
MD-2 in preterm infants was corrected by
treatment of IFN-g (21), suggesting a
correlation between GA and the
expression of IFN-g. However, there was
no correlation between GA and IFN-g in
nasal aspirates in our current cohort
(Figure 3E).
Our data reveal that elevated levels of
IL-4, IL-13, IL1-b, and IL-33 upon
hospitalization with RSV disease are
significant risk factors for severity of disease

















































































































































































































Figure 3. The age-related frequency of nasal aspirate innate lymphoid type 2 cells (ILC2s) and type 2 immune mediators were associated with respiratory
syncytial virus (RSV) disease severity. (A–C) The frequency of ILC2s (A), and the dot plot (B), showing CRTH21ILC2s gated on c-Kit2 CD1271CD1611CD451Lin2
populations, and viral load in nasal aspirates from infants with severe versus moderate RSV (C). (D) A heatmap with hierarchical clustering, illustrating
cytokine expression of individual infants with RSV. (E) The heat map indicates the Spearman rank correlation coefficient (Rho) (varying from positive to
negative correlation; red–white–blue) and P<0.05 (light green to dark green cells) and P.0.05 (white cells). (F–H) Expression of IL-4 (F), ILC2 (G),
and IFN-g (H) in RSV-infected infants <3 months or .3 months of age. GA=gestational age; ns = not significant. **P< 0.01 and ***P<0.001.
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significantly higher levels of IFN-g
(Figure 2) dominate in infants with
moderate disease. These results support
previous studies describing the sustainable
association of elevated IL-4/IFN-g ratios,
IL-1b, and IL-33 levels in either respiratory
secretions or sera (an indication of type 2
bias) with acute RSV bronchiolitis in
infants (13, 23–29). In agreement with our
data, a recent report also revealed that IFN-
g levels in nasal aspirates are lower in
children with severe RSV bronchiolitis (30).
Interestingly, this same study did not report
a change in IL-4 or IL-13 levels between
children with severe or moderate RSV
bronchiolitis in contrast to our current
findings and that of other studies
(25, 26). There are several differences
between these studies that may account
for this discrepancy, including patient
demographics, cohort size, and sampling
methods.
Furthermore, others have observed that
during the acute phase of RSV disease,
circulating CD41 T cells from symptomatic
ambulatory infants expressed a remarkably
greater level of IFN-g compared with those
from hospitalized infants (31), suggesting
that type 1-skewed responses are protective
against severe disease. Similarly, circulating
CD81 T cells expressed a significantly
greater level of IFN-g in hospitalized
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Figure 4. Younger gestational age (GA) positively correlates with higher levels of IL-4 in response to respiratory syncytial virus (RSV) infection and more
severe disease. (A and B) Plots of risk factors for the development of severe RSV, using bivariate logistic regression of (A) background variables and (B)
immune/host-related variables, with pediatric ICU admission status as the dependent variable. The vertical line represents an odds ratio of 1. Odds ratio
with 95% confidence interval; P< 0.05. (C) The combined influence of nasal aspirate levels of IL-4 and GA on the severity of RSV disease in infants was
assessed using multivariable logistic regression. The logarithm of the odds Pr/(12Pr), where Pr is the probability of the disease severity, depends on a
vector of predictors (IL-4 and GA), is logit(Pr) = log[Pr/(12Pr)] =b01bIL43 IL41bGA3GA, where b is a vector of regression coefficients. In the final
logistic regression model, b0 =20.62, bIL4 (0.13 pg/ml)=2.269, and bGA (2.76 wk) =20.709. Duration of symptoms refers to duration of symptoms before
sampling. ILC2= innate lymphoid type 2 cell; LOD= limited of detection; NICU=neonatal ICU; Pro-inf = proinflammatory cytokines.
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disease (32). However, the adaptive
immune responses in the peripheral blood
compartment may not accurately reflect
the local immune responses, especially
during the early phase of the infection. It is
also evident that acute RSV infection
induces a relative predominance of Th2
cytokines in nasal washes compared with
those in plasma from infected children
(33). Having previously demonstrated the
association of the increase in the number
of lung ILC2s with enhanced IL-13
expression in neonatal mouse models of
RSV (11), we, therefore, sought to
determine the ILC2 compartments of the
local innate immune responses using nasal
aspirates collecting within 24 hours of
enrollment. Our study thus reveals the
higher frequency and absolute number of
ILC2s in nasal aspirates from infants with
severe, but not moderate, RSV disease
(Figures 3A and 3B and Figure E5C), and
it furthermore demonstrates that elevated
frequencies of ILC2s increased the risk for
severe RSV (Figure 4B and Table E5A;
P = 0.057). Others have observed
significantly higher GATA3/T-bet
(essential transcript factors for ILC2/Th2
and Th1, respectively) mRNA ratio in
nasal aspirates from hospitalized infants
with severe RSV compared with moderate
RSV (26), suggesting the association of
ILC2 and Th2 polarization with illness
severity. The important role of ILC2 in
mediating type 2 immunity has also been
shown in different lung diseases (34, 35)
and neonatal mouse models of RSV (11).
Although we have no direct evidence that
ILC2s are the source of IL-4/IL-13, the
timing (i.e., early in the infection) and
recent studies demonstrate the ability of
ILC2s to produce these cytokines and to
promote Th2 polarization via either direct
cellular contact (36) or IL-4/IL-13
signaling (35, 37, 38). Our findings
demonstrate that ILC2 frequencies are
highly correlated with IL-4 and IL-13 in
same nasal aspirates (Figures 3D and 3E)
and that these correlate with disease
severity in human infants (Figure 4B and
Table E5A), highlighting the role of ILC2
and type 2 cytokines in RSV human
disease.
Others have shown that the expression
of these type 2 cytokines is age differentiated
in infants infected with RSV. Specifically,
IL-4 levels in nasopharyngeal secretions are
remarkably lower in RSV-infected infants
over 3 months of age versus infants 3
months of age or younger (39). These
findings corroborate our current
observation. Although nasal aspirate levels
of IL-4 and ILC2 were inversely associated
with age at enrollment, IFN-g levels were
significantly greater in RSV-infected infants
over 3 months of age than in infants 3
months of age or younger (Figures 3F–3H
and Table E6). It implies that younger age
at infection is a risk factor for RSV severity
and a potential confounder in immune
responses to RSV infection. However, in
our current cohort, age at enrollment
did not show a statistically significant
association with disease severity (Figure 4A
and Table E5A), and any significant effects
on the association between immune
responses and disease severity (Table E7).
Of note, all patients in our current cohort
are ,1 year old, with 61.2% 3 months old
or younger (Figure E3A). The positively
skewed age distribution may explain
why age at enrollment was not a
significant risk factor for disease severity in
our study.
Understanding the association of viral
load and RSV severity is also essential for
developing antiviral therapies, vaccine
design, and validation of therapeutics/vaccines.
However, the relationship between RSV
severity and viral load is unclear. RSV viral
load has been found to be directly
proportional to LOS, respiratory failure, and
ICU requirements (4, 40–42). Nevertheless,
others have failed to identify a correlation
between viral load in nasopharyngeal lavage
(43) or nasal aspirates with either LOS or
duration of oxygen supplement or severe
bronchiolitis in either infants (44) or
children (45). Our single-time-point data
upon hospital admission for RSV disease
also showed no significant difference in
nasal aspirate viral load between infants
with severe and moderate disease
(Figure 3C). Like other studies (46, 47),
we found that viral load in the nasal
aspirate did not vary by sex, race, age at
enrollment, and prematurity (Figure E2).
Differences in sample size, the time point
of sampling, cohort demographics, and
the target viral genes for viral load
analysis may explain the inconsistency
of viral load data in the literature.
Together with findings from these previous
studies, our data, however, highlight the
complexity of RSV pathogenesis, which is
presumably determined by the interaction
between immune responses and viral
replication.
Overall, our current study examined
viral load and immunological mediators
from nasal aspirates collected within 24
hours of enrollment, and hence represents
the interaction between viral replication and
immune response at a more relevant
infected site and at an earlier phase of
infection relative to other studies (23, 25,
48). Using nasal aspirate collection, which
is more accessible and less invasive than
peripheral blood collection, we demonstrate
a feasible method for characterizing cellular
and humoral components of mucosa innate
immune responses. Thus, our findings
reveal the significant association of elevated
levels of IL-4, IL-13, IL-33, and ILC2s in
nasal aspirates with severe RSV disease,
and a strong correlation between the
frequencies of ILC2s and their associated
cytokines (IL-4 and IL-13) and inducing
cytokine (IL-33) in nasal aspirates from
RSV-infected infants. Although IL-33/ILC2
axis–mediated type-2–biased responses
have been shown in neonatal experimental
models, these represent the first data on
IL-33 and ILC2 responses in RSV-infected
infants at the site of infection. Therefore,
our data provide a translation from our
mouse model (11) to human patients and
suggest the important role of ILC2s in
shaping the immune response in the early
phase of infection. We hypothesized that
levels of ILC2s and their associated
cytokines at the early phase of
infection determine the balance of
Th1/2–adaptive immune responses at the
latter phase of infection in infants with
RSV. Our future studies with longitudinally
collected nasal aspirates will delineate this
possibility.
Our current studies have certain
limitations. Due to the difficulty of finding
cells in nasal aspirates from noninfected
infants, we did not use uninfected infants as
the control population. In addition, the
bioactivity of IL-33 has been elegantly
demonstrated to be highly susceptible to
oxidation (49). Unfortunately, commercial
reagents to specifically detect nonoxidized
forms of IL-33 in human specimens were
not available at the time of our studies, and
thus precluded us from examining these
forms of IL-33. However, the enhanced
levels of IL-33 coinciding with the elevated
ILC2 numbers/frequencies in nasal
aspirates from infants with severe RSV
disease strongly suggest the association of
IL-33/ILC2 with RSV severity. Considering
that more patients with severe disease tend
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to have higher levels of extracellular
mediators, our cytokine data from nasal
aspirates are not normalized for sample
contents (e.g., by total protein) and are
presented as per sample volume. This is
consistent with how viral load is also
quantified. Another limitation of our study
was that we did not examine IL-5, another
ILC2-associated cytokine associated with
induction of eosinophil responses early in
infection. These limitations can be
addressed in further cohorts. n
Author disclosures are available with the text
of this article at www.atsjournals.org.
Acknowledgment: The authors are grateful to
the patients and their parents/guardians who
participated in this research andmade it possible.
References
1. Paes B. Respiratory syncytial virus in otherwise healthy prematurely born
infants: a forgotten majority. Am J Perinatol 2018;35:541–544.
2. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA,
et al. The burden of respiratory syncytial virus infection in young
children. N Engl J Med 2009;360:588–598.
3. El Saleeby CM, Bush AJ, Harrison LM, Aitken JA, Devincenzo JP.
Respiratory syncytial virus load, viral dynamics, and disease severity
in previously healthy naturally infected children. J Infect Dis 2011;204:
996–1002.
4. DeVincenzo JP, El Saleeby CM, Bush AJ. Respiratory syncytial virus
load predicts disease severity in previously healthy infants. J Infect Dis
2005;191:1861–1868.
5. Olchanski N, Hansen RN, Pope E, D’Cruz B, Fergie J, Goldstein M, et al.
Palivizumab prophylaxis for respiratory syncytial virus: examining the
evidence around value. Open Forum Infect Dis 2018;5:ofy031.
6. Russell CD, Unger SA, Walton M, Schwarze J. The human immune
response to respiratory syncytial virus infection. Clin Microbiol Rev
2017;30:481–502.
7. Mjösberg JM, Trifari S, Crellin NK, Peters CP, van Drunen CM, Piet B,
et al. Human IL-25– and IL-33–responsive type 2 innate lymphoid cells
are defined by expression of CRTH2 and CD161. Nat Immunol 2011;
12:1055–1062.
8. Dhariwal J, Cameron A, Trujillo-Torralbo M-B, Del Rosario A, Bakhsoliani
E, Paulsen M, et al.; MRC-GSK Strategic Alliance Consortium.
Mucosal type 2 innate lymphoid cells are a key component of the
allergic response to aeroallergens. Am J Respir Crit Care Med 2017;
195:1586–1596.
9. Poposki JA, Klingler AI, Tan BK, Soroosh P, Banie H, Lewis G, et al.
Group 2 innate lymphoid cells are elevated and activated in
chronic rhinosinusitis with nasal polyps. Immun Inflamm Dis 2017;5:
233–243.
10. Neill DR, Wong SH, Bellosi A, Flynn RJ, Daly M, Langford TKA, et al.
Nuocytes represent a new innate effector leukocyte that mediates
type-2 immunity. Nature 2010;464:1367–1370.
11. Saravia J, You D, Shrestha B, Jaligama S, Siefker D, Lee GI, et al.
Respiratory syncytial virus disease is mediated by age-variable
IL-33. PLoS Pathog 2015;11:e1005217.
12. Saluzzo S, Gorki A-D, Rana BMJ, Martins R, Scanlon S, Starkl P, et al.
First-breath-induced type 2 pathways shape the lung immune
environment. Cell Reports 2017;18:1893–1905.
13. Garcı́a-Garcı́a ML, Calvo C, Moreira A, Cañas JA, Pozo F, Sastre B,
et al. Thymic stromal lymphopoietin, IL-33, and periostin in
hospitalized infants with viral bronchiolitis. Medicine (Baltimore)
2017;96:e6787.
14. Perkins SM, Webb DL, Torrance SA, El Saleeby C, Harrison LM, Aitken
JA, et al. Comparison of a real-time reverse transcriptase PCR assay
and a culture technique for quantitative assessment of viral load in
children naturally infected with respiratory syncytial virus. J Clin
Microbiol 2005;43:2356–2362.
15. Resch B, Gusenleitner W, Müller W. The impact of respiratory syncytial
virus infection: a prospective study in hospitalized infants younger
than 2 years. Infection 2002;30:193–197.
16. Horn SD, Smout RJ. Effect of prematurity on respiratory syncytial virus
hospital resource use and outcomes. J Pediatr 2003;143(Suppl)
S133–S141.
17. Gunville CF, Sontag MK, Stratton KA, Ranade DJ, Abman SH, Mourani
PM. Scope and impact of early and late preterm infants
admitted to the PICU with respiratory illness. J Pediatr 2010;157:
209–214, e1.
18. McLaurin KK, Farr AM, Wade SW, Diakun DR, Stewart DL. Respiratory
syncytial virus hospitalization outcomes and costs of full-term and
preterm infants. J Perinatol 2016;36:990–996.
19. Ballow M, Cates KL, Rowe JC, Goetz C, Desbonnet C. Development of
the immune system in very low birth weight (less than 1500 g)
premature infants: concentrations of plasma immunoglobulins and
patterns of infections. Pediatr Res 1986;20:899–904.
20. Conway SP, Dear PR, Smith I. Immunoglobulin profile of the preterm
baby. Arch Dis Child 1985;60:208–212.
21. Tissières P, Ochoda A, Dunn-Siegrist I, Drifte G, Morales M, Pfister R,
et al. Innate immune deficiency of extremely premature neonates can
be reversed by interferon-g. PLoS One 2012;7:e32863.
22. Rallabhandi P, Phillips RL, Boukhvalova MS, Pletneva LM, Shirey KA,
Gioannini TL, et al. Respiratory syncytial virus fusion protein–induced
Toll-like receptor 4 (TLR4) signaling is inhibited by the TLR4
antagonists Rhodobacter sphaeroides lipopolysaccharide and
eritoran (E5564) and requires direct interaction with MD-2. MBio
2012;3:pii:e00218–12.
23. Román M, Calhoun WJ, Hinton KL, Avendaño LF, Simon V, Escobar
AM, et al. Respiratory syncytial virus infection in infants is associated
with predominant Th-2–like response. Am J Respir Crit Care Med
1997;156:190–195.
24. Legg JP, Hussain IR, Warner JA, Johnston SL, Warner JO. Type 1 and
type 2 cytokine imbalance in acute respiratory syncytial virus
bronchiolitis. Am J Respir Crit Care Med 2003;168:633–639.
25. Hassan MA, Eldin AM, Ahmed MM. T-helper2/T-helper1 imbalance in
respiratory syncytial virus bronchiolitis in relation to disease severity
and outcome. Egypt J Immunol 2008;15:153–160.
26. Caballero MTSM, Serra ME, Acosta PL, Marzec J, Gibbons L, Salim M,
et al. TLR4 genotype and environmental LPS mediate RSV
bronchiolitis through Th2 polarization. J Clin Invest 2015;125:
571–582.
27. Bendelja K, Gagro A, Bace A, Lokar-Kolbas R, Krsulovic-Hresic V,
Drazenovic V, et al. Predominant type-2 response in infants with
respiratory syncytial virus (RSV) infection demonstrated by cytokine
flow cytometry. Clin Exp Immunol 2000;121:332–338.
28. Dı́az PV, Valdivia G, Gaggero AA, Bono MR, Zepeda G, Rivas M, et al.
Pro-inflammatory cytokines in nasopharyngeal aspirate from
hospitalized children with respiratory syncytial virus infection with or
without rhinovirus bronchiolitis, and use of the cytokines as
predictors of illness severity. Medicine (Baltimore) 2015;94:e1512.
29. Bertrand P, Lay MK, Piedimonte G, Brockmann PE, Palavecino CE,
Hernández J, et al. Elevated IL-3 and IL-12p40 levels in the lower
airway of infants with RSV-induced bronchiolitis correlate with
recurrent wheezing. Cytokine 2015;76:417–423.
30. Thwaites RS, Coates M, Ito K, Ghazaly M, Feather C, Abdulla F, et al.
Reduced nasal viral load and IFN responses in infants with
respiratory syncytial virus bronchiolitis and respiratory failure. Am J
Respir Crit Care Med 2018;198:1074–1084.
31. Pinto RA, Arredondo SM, Bono MR, Gaggero AA, Dı́az PV. T helper 1/T
helper 2 cytokine imbalance in respiratory syncytial virus infection is
associated with increased endogenous plasma cortisol. Pediatrics
2006;117:e878–e886.
32. Chen ZM. Mao JH, Du LZ, Tang YM. Association of cytokine responses
with disease severity in infants with respiratory syncytial virus
infection. Acta Paediatr 2002;91:914–922.
33. Bermejo-Martin JF, Garcia-Arevalo MC, De Lejarazu RO, Ardura J,
Eiros JM, Alonso A, et al. Predominance of Th2 cytokines, CXC
chemokines and innate immunity mediators at the mucosal level
during severe respiratory syncytial virus infection in children. Eur
Cytokine Netw 2007;18:162–167.
ORIGINAL ARTICLE
1422 American Journal of Respiratory and Critical Care Medicine Volume 200 Number 11 | December 1 2019
 
34. Gold MJ, Antignano F, Halim TY, Hirota JA, Blanchet MR, Zaph C, et al.
Group 2 innate lymphoid cells facilitate sensitization to local, but not
systemic, TH2-inducing allergen exposures. J Allergy Clin Immunol
2014;133:1142–1148.
35. Pelly VS, Kannan Y, Coomes SM, Entwistle LJ, Rückerl D, Seddon B,
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